Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
3.
J Pain Res ; 13: 565-573, 2020.
Article in English | MEDLINE | ID: mdl-32256104

ABSTRACT

BACKGROUND: Although ultrasound-guided transversus abdominis plane block (TAPB) is widely used in multimodal analgesia after cesarean delivery (CD), the complications of TAPB during analgesia after CD have rarely been reported. METHODS: A total of 84 cases of CD were randomly assigned to either a ropivacaine group (R group) or ropivacaine + dexamethasone group (RD group) in this double-blind trial. The pain site and pain degree at rest and during activity at 2 h, 6 h, 10 h, 12 h, 14 h, 16 h, 20 h, and 24 h after maternal surgery were recorded. The consumption of opioids at 24h, postoperative nausea, vomiting, exhaustion, and other adverse reactions were recorded. RESULTS: A total of 80 patients were included in the analysis of results. A total of 19 patients developed ISP, 14 in the R group and 5 in the RD group. The incidence of ISP in the R and RD groups was 35% and 12.5%, respectively. The results described above showed that combining dexamethasone with ropivacaine reduced the incidence of ISP, and the difference was statistically significant (P<0.05). Two groups of women with positive ISP had higher values of opioid consumption than women with negative ISP, but the difference was not significant. CONCLUSION: Dexamethasone as an adjuvant for ropivacaine can effectively relieve the ISP of ultrasound-guided TAPB after CD, and can enhance the analgesic effect of ropivacaine.

4.
Zhong Nan Da Xue Xue Bao Yi Xue Ban ; 30(4): 420-3, 2005 Aug.
Article in Chinese | MEDLINE | ID: mdl-16190388

ABSTRACT

OBJECTIVE: To investigate the effects of ulinastatin (UTI) on cerebral inflammatory response during cardiopulmonary bypass (CPB). METHODS: Twenty-four NYHA II-III patients (13 males and 11 females) aged 23-45 years, undergoing elective cardiac valve replacement under hypothermic CPB were randomly divided into 2 groups: ulinastatin group (Group U, n=12) and control group (Group C, n=12). In group U, UTI (1.2 x 10(4) U/kg) was given intravenously after the induction of anesthesia, 0.6 x 10(4) U/kg UTI was added to the priming solution, and 0.6 x 10(4) U/kg UTI was given about 5 min before the aortic decamping. In Group C, normal saline was given instead of UTI. Internal jugular vein was cannulated and the catheter was advanced retrogradely till jugular bulb. Blood samples were taken simultaneously from artery and jugular bulb after induction of anesthesia (T1), 60 min (T2) and 6 h (T3) after discontinuation of CPB for determination of TNFalpha, IL-6, IL-8 and IL-10. The juguloarterial gradients of these cytokines (deltaTNFalpha, deltaIL-6, deltaIL-8, and deltaIL-10) were calculated. RESULTS: In Group C, arterial levels of TNFalpha, IL-6, IL-8, IL-10 at T2 and T3, deltaTNFalpha, deltaIL-8 and deltaIL-10 at T2, deltaTNFalpha, deltaIL-6 and deltaIL-10 at T3 significantly increased (P < 0.01). deltaIL-8 increased at T3 (P < 0.05). In Group U, arterial levels of IL-6, IL-8, IL-10 at T2, arterial levels of IL-6, IL-8,IL-L-10 and deltaTNFalpha, deltaIL-8 at T3 significantly increased (P < 0.01). Arterial levels of TNFalpha at T2 and T3, deltaTNFalpha, deltaIL-10 at T2, deltaIL-6 at T3 increased (P < 0.05). Arterial levels of TNFalpha, IL-6 and deltaTNFalpha, deltaIL-8 at T2, arterial levels of TNFalpha and deltaIL-6 at T3 in Group U were lower than those in Group C (P < 0.05). Arterial levels of IL-6 at T3, IL-8 at T2 and T3 in Group U were significantly lower than those in Group C (P < 0.01). Arterial levels of IL-10 and deltaIL-10 at T3 in Group U were higher than those in Group C (P < 0.05). CONCLUSION: Systemic and cerebral activation of inflammatory response during CPB can be alleviated by ulinastatin.


Subject(s)
Cardiopulmonary Bypass/adverse effects , Encephalitis/etiology , Encephalitis/prevention & control , Glycoproteins/therapeutic use , Adult , Encephalitis/metabolism , Female , Heart Valve Prosthesis Implantation , Humans , Interleukin-10/blood , Interleukin-6/blood , Interleukin-8/blood , Male , Middle Aged , Trypsin Inhibitors/therapeutic use , Tumor Necrosis Factor-alpha/metabolism
5.
Zhong Nan Da Xue Xue Bao Yi Xue Ban ; 29(5): 569-71, 2004 Oct.
Article in Chinese | MEDLINE | ID: mdl-16137049

ABSTRACT

OBJECTIVE: To investigate the effect of ulinastatin (UTI) on human blood coagulation and platelet aggregation in orthopaedic surgery. METHODS: Thirty ASA I-II patients without blood dyscrasia and blood coagulation obstacle were randomly divided into two groups: Group I (UTI group, n=15) in which patients received UTI 5000 U/kg, and Group II (control group, n=15) in which patients received NS 100 ml. PT, TT, APTT, IB, INR and PAG1, PAG5, and PAGM were measured at 3 points: pre-infusion (T0), 1 hour after the infusion (T1), and 2 hours after the infusion (T2). RESULTS: Compared with the saline group, APTT and PT of UTI group were prolonged significantly than the baseline (before infusion). In Group I, after the infusion, APT, TT and PT were prolonged significantly than before the infusion. CONCLUSION: UTI 5000 U/kg can ameliorate orthopaedic patients and blood coagulation status,which may reduce microthrombus syndrome in the operation and prevent venous thrombosis after the operation.


Subject(s)
Arthroplasty, Replacement, Hip/adverse effects , Blood Coagulation/drug effects , Glycoproteins/therapeutic use , Platelet Aggregation/drug effects , Venous Thrombosis/prevention & control , Adult , Aged , Female , Humans , Male , Middle Aged , Postoperative Complications/prevention & control , Trypsin Inhibitors/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...